
Valvular heart disease and prosthetic valve

Surface anatomy


- MV: behind the Lt ½ of the sternum opp. the 4th coastal cartilage
- AV: behind the Lt $\frac{1}{2}$ of the sternum opp. The 3rd ICS
- TV: behind the Rt ½ of the sternum opp. The4th ICS
- PV: behind the medial end of the 3rd LT CC & adjoining part of the sternum



Anatomy

- MV:
- 2Cusps, Anterior and posterior
- The Ant is the larger
- Intervenes bet. A-V and aortic orifice
- AV:
- 3 semilunar cusps, ant (RT), post. Wall (LT and post)
- TV;
- 3cusps, ant, septal, post.
- PV;
- 3 semilunar cusps one post. (lt) tow ant(ant and rt)

Figure 3. The relationships of the mitral valve are important.



Fedak PW et al. Circulation. 2008;117:963-974



Aortic stenosis Aetiology

Infants, children, adolescents

- Congenital aortic stenosis
- Congenital subvalvular aortic stenosis
- Congenital supravalvular aortic stenosis

Young adults to middle aged


Calcification and fibrosis of congenitally bicuspid valve Rheumatic aortic disease

Middle aged to elderly

Calcification of bicuspid valve Senile degenerative aortic stenosis


Rheumatic aortic disease

AS







AVS tricuspid and bicuspid calcifications









Pathophysiolgy of AS

- Except in the congenital forms, AS develops slowly
- The LV becomes increasingly hypertrophied, and coronary blood flow may become inadequate
- The fixed outflow obstruction limits the increase in C.O required on exercise.
- The progressive LV outflow obstruction results in increased LV mass.

Symptoms of AS

- Exertional dyspnoea
- Angina
- Pulmonary edema
- Exertional syncope
- Sudden death


Signs of AS

- Ejection systolic murmur
- Slow rising carotid pulse
- Reduce pulse pressure
- LV hypertrophy
- Signs of LV failure (crepitations, pulmonary edema)

Investigations

- ECG
- CXR
- **ECHO**
- CATH

ECG in AS



- LVH with strain (slightly wide QRS in I,II,III and have increased amplitude)
- Large S in V2 and large R in V6 with T wave inversion in V6

CXR in AS

AORTIC STENOSIS,
 dilated ascending aorta,
 normal heart size



ECHO criteria for assessment of aortic stenosis

severity	Mean gradient(mmhg)	Aortic valve area (cm2)
mild	<25	>1.5
moderate	25-45	1-1.5
severe	>45	<1
critical	>70	<0.7

Management


■ Medical; Medical treatment essentially is reserved for patients who have complications of AS such as heart failure, infective endocarditis, or arrhythmias.

Surgical; The primary management of symptomatic patients with valvular AS is interventional

Aortic regurgitation

Aetiology

- Congenital
- Bicuspid valve, or disproportionate cusps
- Acquired
- Rheumatic disease
- Infective endocarditis
- Trauma
- Aortic dilatation: marfan syndrome, atheroma, syphilis, ankylosing spondylitis



pathophysiology

- The stroke output of the LV may be doubled or trebled
- LV dilated and hypertrophied
- In acute AR, The LV poorly accommodates the abrupt increase in end-diastolic volume, and diastolic filling pressure increases rapidly. The rise in LV filling pressure is transmitted to the LA, pulm. veins, and pulm. capillaries, leading to pulm.edema and congestion.

Clinical features symptoms:

- Mild AR;
- asymptomatic
- palpitations
- Severe AR;
- Symptoms of heart failure
- angina


Signs of AR

- Large volume or 'collapsing' pulse
- Bounding peripheral pulses
- Early diastolic murmur
- Systolic murmur of increased stroke volume
- Signs of heart failure

Investigations

- ECG
- CXR
- MRI, CT scan
- ECHO
- CATH

ECG in AR



- LVH with strain (slightly wide QRS in I,II,III and have increased amplitude
- Large S in V2 and large R in V6 with T wave inversion in V6
- Left atrial enlargement Left axis deviation

CXR in AR

- Enlarged thoracic aorta
- cardiomegaly



ECHO in AR

- Dilated LV
- Hyperdynamic ventricle
- Fluttering anterior mitral leaflet
- Doppler detects reflux

Treatment of AR

Medical

- Vasodilator therapy.
- Treat asymptomatic patients with chronic severe AR and dilated but normal LV systolic function medically, and monitor their cases for development of indications for AVR. Patients with mild AR and normal LV size require no therapy other than endocarditis prophylaxis
- The treatment of choice for acute AR is AVR. Medical therapy can be used as a bridge to surgery but should not replace it.

Treatment of AR

Surgical

- Surgical treatment of AR almost always requires replacement of the diseased valve with a prosthetic valve
- AVR is indicated when AR is beginning to cause sx or when an enlarging heart or progressive ECG changes give evidence of increasing LV overload

Surgical treatment of AR

- Asymptomatic patients with evidence of LV systolic dysfunction (EF < 0.50) should undergo AVR.
- Asymptomatic patients with severe AR and normal LV function but with severe LV dilatation (end-diastolic dimension >75 mm or end-systolic dimension >55 mm) should undergo AVR..


Prosthetic heart valve

- The two main prosthetic valve designs include:
- mechanical
- bioprosthetic(tissue) heart valves

Mechanical valves

ball and cage

bileaflet



Bioprosthetic Valves

Aortic homograft


- Human tissue valves
- autograft
- homograft
- Animal tissue valves
- Heterograft or xenograft



Animal Tissue Valves

The most commonly used animal tissues are: porcine, which is valve tissue from a pig, and bovine pericardial tissue, which is from a cow.

■ The leaflet valve tissue of the animals is inspected, and the highest quality leaflet tissues are then preserved. They are then stiffened by a tanning solution, most often glutaraldehyde.




Transcatheter Aortic Valve Intervention


Recently, percutaneous valve replacement has been developed. TAVI is a reasonable alternative to surgical AVR in patients at high surgical risk. .


Procedure & Hardware

LA + Conscious sedation/ GA, hemodynamic stability [SBP~120 mm Hg / MAP >75 mm Hg]



TAVI Route








Transfemoral Valve Implantation

Transapical Valve Implantation

Transaortic Valve Implantation

images



How to choose a valve

- Mechanical valve in patients < 65years.</p>
- Tissue valves in patients > 65 years
- Tissue valves in patients whose life expectancy is < 10 year
- Tissue valve in patients who have problems which are likely to cause life threatening bleeding.

Valve types





Bioprosthetic/Tissue

No lifetime warfarin

Less durability

Mechanical valve

Need for warfarin

Better durability

ACC/AHA guideline summary: Antithrombotic therapy in patients with mechanical heart valves

Class I - There is evidence and/or general agreement that antithrombotic therapy in indicated in patients with mechanical heart valves in the following settings:

- Warfarin to achieve a goal INR of 2.0 to 3.0 after:
- 1. Aortic valve replacement (AVR) with bileaflet mechanical or Medtronic Hall valves if no risk factors * are present.
- Warfarin to achieve a goal INR of 2.5 to 3.5 after:
- 1. AVR with bileaflet mechanical or Medtronic Hall valves if risk factors* are present.
- 2. AVR with Starr-Edwards or disc valves other than Medtronic Hall if no risk factors* are present.
- 3. Mitral valve replacement (MVR) with any mechanical valve.
- Role of aspirin:
- After AVR or MVR in patients who cannot take warfarin, at a dose of 75 to 325 mg/day.
- 2. At a dose of 75 to 100 mg/day in addition to warfarin in all patients with mechanical valves and in patients with biological valves who have risk factors*.

Class IIa - The weight of evidence or opinion is in favor of the usefulness of antithrombotic therapy in patients with mechanical heart valves in the following settings:

• In the first three months after AVR, warfarin to achieve a goal INR of 2.5 to 3.5.

Class IIb - The weight of evidence or opinion is less well established for the usefulness of antithrombotic therapy in patients with mechanical heart valves in the following setting:

 In high-risk patients in whom aspirin cannot be used, clopidogrel (75 mg/day) or warfarin to attain a goal INR of 3.5 to 4.5.

Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006;

^{*} Risk factors include atrial fibrillation, prior thromboembolism, left ventricular dysfunction, and a hypercoagulable state.

Data from Bonow, RO, Carabello, BA, Chatterjee, K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on

Mitral stenosis

- Aetiology
- Isolated MS accounts for 25% of all rheum. Heart dis., and an additional 40% have mixed MS and MR
- 2/3 of cases occurs in women
- Acquired MS is almost entirely rheum. in origin

Aetiology of MS

- Acquired MS results from long-term damage to the mitral valve and its supporting structures.:
- In rheumatic heart disease
- SLE
- Amyloidosis
- Postsurgical acquired MS, such as MS occurring after mitral valve annuloplasty for severe MR.



Sever MS MS

FISH MOUTH (RHD)





Pathophysiology of MS

- The normal adult mitral valve orifice cross-sectional area is 4-6 cm2.
- When reduced to 2 cm2, hemodynamically significant MS occurs. WHEN <1cm2 it is critical
- As a compensating mechanism, pulmonary vasoconstriction develops, causing pulmonary hypertension.
- Severe MS results in decreased cardiac output

MS Pathophysiology

- Progressive Dyspnea (70%): LA dilation →
 pulmonary congestion (reduced emptying)
 worse with exercise, fever, tachycardia, and pregnancy
 Increased Transmitral Pressures: Leads to left atrial enlargement and atrial fibrillation.

 Right heart failure symptoms: due to Pulmonary venous HTN
- **Hemoptysis:** due to rupture of bronchial vessels due to elevated pulmonary pressure


Signs of MS

- AF
- Loud 1st heart sound, opening snap, mid-diastolic murmur
- Signs of raised pulm capillary pressure (crepitations,pul edema, effusions)
- Signs of pul HTN.

Investigations of MS


- ECG
- LA hypertrophy if not in AF
- Left atrial enlargement is illustrated by increased P wave duration in lead II, top ECG, and by the prominent negative P terminal force in lead V1, bottom tracing





Investigations of MS

- **ECG**
- RVH




CXR

Chest radiograph of a patient with mitral stenosis shows pulmonary hypertension, mild cardiomegaly and enlargement of the left atrium (arrow) and pulmonary artery



ECHO

- Thickened immobile cusps
- Reduced rate of diastolic filling
- Reduced valve area



Treatment of MS medical

- Asymptomatic patients with mild MS require yearly followup
- For the patient with signs or symptoms of CHF, diuretics may provide benefit
- RX of Tachyarrhythmias
- Electrophysiologic ablation of atrial fibrillation or flutter circuits may be performed in the catheterization laboratory

Percutaneous mitral balloon valvuloplasty

- Indications for this procedure are similar to those for surgery, including
- CHF unresponsive to medical management
- asymptomatic patients with a pulmonary artery (PA) systolic pressure of 50 mm Hg or greater.
- In some centers, the procedure is successful in 80-90% of selected cases. The procedural mortality rate is 1-2%.

Treatment surgical

- Indications:
- Symptomatic mitral stenosis especially if peripheral emboli
- Mitral valve area less than 1 cm2
- Mitral valvotomy
- Commissurotomy consists of an incision of fused mitral valve commissures and shaving of thickened mitral valve leaflets.
- Fused chordae tendineae and papillary muscles can be divided to relieve subvalvular stenosis.

Treatment surgical

 Mitral valve replacement with mechanical valve or bioprosthesis




Figure 11-7 Mitral valve replacement, through a median sternotomy incision and opening into left atrium from the right side anterior to the right pulmonary veins (see legend of Fig. 11-4 for details). Two-venous cannulae are illustrated, but a single venous cannula can be used instead. A Cooley left atriotomy retractor is used (not shown).

- (a) As described in the text, the incision in the mitral leaflet is begun with the knife anteriorly and about 2 mm from the anulus, where nearly always the leaflet is pliable and relatively free of disease.
- (b) As the incision is carried leftward with the knife or scissors toward the anterolateral commissure, the underlying papillary muscle and fused chordae come into view and are cut.
- (c) As the incision is carried across the anterplateral (illustrated here) and posteromedial commissural areas, care is taken to stay close




Figure 11-7 (continued).

(h) When an interrupted suture line technique is chosen (GLH), the first suture is placed at the anterolateral commissure in the 10-o'clock position. Each stitch (No. 2 silk) is passed first through the sewing ring of the valve (the valve remains outside the chest, being held by the assistant with the aid of a valve holder) and then through the anulus of the patient, with the needle held in reverse (backhand) fashion and passed from the left ventricular to the left atrial side. Each stitch passes just inside the anulus, and emerges through the adjacent portion of the atrial wall; care is taken that it not pass deeply enough to damage the underlying circumflex coronary artery. Suturing continues in a counterclockwise direction around exactly half the circumference of the host valve ring (to the 4-o'clock position), as well as around one-half the circumference of the sewing ring of the prosthesis. When the sutures are placed between the 6-o'clock and 4-o'clock positions, the needle is best passed forehand. The two ends of each of these sutures are clipped together with a hemostat just after the suture is placed; the handle of the hemostat is threaded onto a large "safety pin" outside the chest, to prevent the sutures from becoming crossed when they are tied later. With all the posterior sutures in position, the safety pin is closed. (Figure continues.)

MVR

True supra-annular valve-Supra-X

23 mm valve



- Supra- and extra-annular valve and stent =
 - Implant larger valve
 - Maximizes flow area

Intra-annular valves

21 mm valve



Intra-annular
valve with
intra-annular stent =
Reduced flow area

21 mm valve



Supra-annular sewing ring with intra-annular stent = Reduced flow area

Mitral Regurgitation

- Aetiology
- Acute MR:

- Ruptured chordae or papillary muscle due to acute myocardial infarction or trauma
- Perforation of the mitral valve leaflet
- Acute failure of a prosthetic valve


Mitral Regurgitation

- Aetiology
- Chronic MR:
 - Mitral valve prolapse
 - Rheumatic heart disease
 - Coronary artery disease
 - Connective-tissue disorder
 - Prosthetic valves



Valvular Regurgitation

A condition in which blood leaks in the wrong direction because one or more heart valves closes improperly. Mitral valve prolapse (illustrated here) is a common cause of regurgitation.



Pathophysiology

- In chronic MVR, the distensibility of the LA and LV are increased over time.
- This dilatation of the left atrium decreases left atrial pressures, thus increasing preload.
- The left ventricle dilatates and, hypertrophied generates a larger stroke volume without a significant rise in wall stress.

CLINICAL

Symptoms

- Acute MR
- Sx of acute pulm edema and reduced CO
- Chronic progressive MR
- Exertional dyspnea, nocturnal dyspnea, palpitations(AF, atrial flutter, increased stroke volume)
- Sx of pulm edema
- Sx of diminished CO
- Sx of right sided HF

Signs of MR

- AF/ Flutter
- Cardiomegaly- displaced hyperdynamic apex beats
- Apical systolic murmur, thrill
- Signs of raised pulm capillary pressure (crepitations, pulm edema, effusions)
- Signs of pulm HTN

Investigations for MR

- ECG
- LAH (if not in AF)
- LVH
- CXR
- Enlarged LA, LV
- Signs of pulm venous HTN
- Signs of pulm edema if acute
- ECHO
- Dilated LA, LV
- Dynamic LV(UNLESS AF PREDOMINATE)
- Regurgitation detected on Doppler

CXR MR

- Marked cardiomegaly
- Pulm venous HTN
- LA appendage enlargement

TREATMENT of MR

Medical

Any patient with acute or chronic mitral valve regurgitation with hemodynamic compromise should be evaluated for acute myocardial infarction.

- Afterload-reducing agents
- If atrial fibrillation is encountered, digitalis therapy is considered
- Prophylactic antibiotics are administered prior to any interventional treatment


TREATMENT OF MR SURGICAL

- Indications for surgical Intervention
- Acute MR with congestive heart failure or cardiogenic shock
- Acute endocarditis
- Class III/IV symptoms (ie, patient symptomatic while at rest or with minimal activity)
- Systemic emboli

MITRAL RECONSTRUCTIVE SURGERY

REPAIR TECHNIQUES

LEVEL	MANEUVER
ANNULUS	REDUCTION
LEAFLETS	RESECTION ENLARGEMENT
CHORDS	RESECTION SHORTENING TRANSPOSITION REPLACEMENT
COMMISSURES	SPLITTING RESECTION
PAPPILARY MUSCLES	SPLITTING SHORTENING REPOSITIONING







Figure 4. Correction of a prolapsing anterior leaflet with placement of polytetrafluoroethylene (PTFE) neochordae. (Reprinted with permission from Carpentier A, Adams DH, Filsoufi F. Carpentier's Reconstructive Valve Surgery. From Valve Analysis to Valve Reconstruction. 2010 Saunders Elsevier.).





Repaired mitral valve